GFPrint and PredLung nominated finalists in the AstraZeneca’s BeLung Innovation challenge

Two machine learning frameworks developed in Topazium, GFPrint™ and PredLung™, have been used to extract important information from cancer patients, in particular from lung cancer patients, that may serve to design better therapies, generate virtual biomarker signatures and predict patient outcomes. Three case studies are presented, focused on i) the discovery of potential novel targets…